Bruce Lizanne M sold $51K of SLVM

Bruce Lizanne M sold 1,230 shares of Sylvamo Corp (SLVM) at $41.70 on 2026-06-15.

Original reporting
SEC EDGAR · Bruce Lizanne M
Published Jun 16, 2026, 3:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 3:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SLVM
Neutral
high confidence
Mentioned
$SLVM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SLVMNeutralLow
01

Why it matters

A director’s open-market sale is disclosed with trade date, price, and post-transaction holdings; it does not include new financial results, guidance, or regulatory/contract events.

02

Market read

Traders may note the insider sale, but there is no accompanying fundamental catalyst to drive a sustained repricing.

03

What to watch

The article doesn’t state whether the director’s remaining holdings are subject to other plans, nor does it provide context on prior sales frequency or size versus typical behavior.

Relevance 3/10Novelty 8/10Timing: SEC Form 4 filed 2026-06-16 for a sale executed 2026-06-15

Background

The article is an SEC Form 4 insider transaction disclosure for Sylvamo Corp.

Company-level read

Ticker impact

$SLVMNeutralHigh confidence
Context

Sylvamo director Bruce Lizanne M sold 1,230 shares in an open-market transaction at $41.70 on 2026-06-15 (Form 4).

Expected impact

Low near-term impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an insider sale (not a buy), small relative to typical market moves, and provides no new operating or guidance catalyst.

Market effects

No sector read-through; this is a single-company insider transaction without operational disclosures.

None indicated.

None indicated.

Counterpoint

Insider sales can reflect diversification or liquidity needs rather than a negative view; the absence of a 10b5-1 plan detail reduces interpretability but doesn’t confirm bearish intent.

Key entities

  • Sylvamo Corp

    Company whose director insider sale is reported on SEC Form 4.

  • Bruce Lizanne M

    Director who sold 1,230 shares at $41.70 on 2026-06-15.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SLVMMedAI 8/10

Sylvamo Q3 Earnings Call Highlights

Sylvamo (SLVM) reported Q3 adjusted EBITDA improved by $25M due to price increases, with flat volume. Input costs rose by $6M, but the company expects to mitigate further increases. Projects at Eastover and Sumter mills are on track, with expected capacity expansions. The company declined to update free cash flow targets post-Europe transaction but reaffirmed capital allocation priorities, including dividends and share repurchases.

$SLVMMed

Sylvamo Corp (SLVM) (Q3 2026) Earnings Call Highlights: Adjusted EBITDA Nearly Doubles

Sylvamo Corp (SLVM) reported Q3 2026 adjusted EBITDA of $128M, nearly doubling from Q2. CEO John Sims and CFO John Devlin discussed 2027 outlook, noting uncertainties but expecting $25M of non-repeat items. They also addressed the Europe deal, Sumter sheeter expansion, and cost mitigation strategies. The company's shareholder rights plan will expire on Nov 9, 2026. North America shipments are expected to be flat in 2027, with industry decline of about 2% in 2026.

Med

Sylvamo Corporation Q3 2026 Earnings Call Summary

Sylvamo Corporation reported Q3 2026 earnings, highlighting a strategic pivot to North and Latin America, operational improvements, and planned divestiture of European business by Q1 2027. The company expects $6M higher input costs in Q4 2026 and projects flat North American volume in 2027. Management deferred new free cash flow targets until the European sale is finalized, prioritizing balance sheet strength and high-return projects.

$SLVMMed

Sylvamo (SLVM) Q3 2026 Earnings Call Transcript

Sylvamo (SLVM) reported Q3 2026 net sales of $645 million, adjusted EBITDA of $128 million, and adjusted earnings of $1.33 per share. The company agreed to divest European operations, retaining a 20% interest, and plans capacity expansions in the U.S. Management highlighted price increases and operational improvements but noted ongoing cost pressures. The board did not renew the shareholder rights plan. (350 characters)

$SLVMMed

Sylvamo Reports Third Quarter 2026 Earnings

Sylvamo (SLVM) reported Q3 2026 earnings, with net sales of $645M from continuing operations and net income of $85M ($2.13 per share). The company announced a potential sale of its Europe business to Midas Atlantic Partners and The Najafi Companies. Sylvamo declared a $0.45 per share dividend and is investing in strategic projects at its Eastover mill. The company expects to focus on Latin America and North America post-transaction.